Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4689-4696

  Nashimoto, Atsushi ^a   Yabusaki, Hiroshi ^a   Nakagawa, Satoru ^a   Takii, Yasugiro ^a   Tsuchiya, Yoshiaki ^a   Otsuo, Tanaka ^a  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

Advanced gastric cancer; Cisplatin; Neoadjuvant chemotherapy; Preoperative chemotherapy; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 75149136556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Guideline for Gastric Cancer. 1st English ed. Japanese Research Society for Gastric Cancer. Kanehara, Tokyo, 1995.
2. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsauka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y and Okajima K: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group Study 9501. J Clin Oncol 22: 2767-2773, 2004.
3. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group: D2 lymphadenectomy alone or with paraaortic lymph node dissection for gastric cancer. N Engl J Med 359: 453-462, 2008.
4. Sasako M, Sano T, Yamamoto S, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M, for the Japan Clinical Oncology Group (JCOG9502): Left thoracicoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7: 644-651, 2006.
5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, and Fleig WE: Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chura YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 355: 11-20, 2006.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita M, Nishizaki K, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura M, Yamaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215-221, 2008.
8. Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nakayama S, Fukushima M, Takabayashi A and Sakai Y: Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer 9: 129-135, 2006.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
10. Ajani JA, Mansfield PF, Janjan N, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS and Gunderson LL: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22: 2774-2780, 2004.
11. Japanese Classification of Gastric Carcinoma. 13th Edition, Kanehara, Tokyo, 1999.
12. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drag S-1 (1 M tegafur-0.4 M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
14. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
15. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, hirao M, Tsujinaka T, Imano M, Furakawa H, Tsukuma H and Taguchi T: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 75: 65-71, 2007.
16. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T and Sugihara K: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94(8): 1130-1135, 2006.
17. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2(11 Pt 1): 3402-3407, 2006.
18. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu M, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjyo F and Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12): 1803-1808, 2006.
19. Nakajo A, Hokita S, Ishigami S, Miyazono F, Rtoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridma K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T and Kyushu Taxol TS-1 Study Group: a multicenter phase II study of biweekly Paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric caner. Cancer Chemother Pharmacol 2(6): 1103-1109, 2008.
20. Narahara H, Fujirtani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H and Taguchi T: Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 4(1-2): 37-41, 2008.
21. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; and ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.